AMPHOTERICIN-B AND ITS DELIVERY BY LIPOSOMAL AND LIPID FORMULATIONS

被引：65

作者：

GATES, C ^{[1
]}

PINNEY, RJ ^{[1
]}

机构：

[1] UNIV LONDON,SCH PHARM,DEPT PHARMACEUT,MICROBIOL SECT,BRUNSWICK SQ,LONDON WC1N 1AX,ENGLAND

来源：

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS | 1993年 / 18卷 / 03期

关键词：

D O I：

10.1111/j.1365-2710.1993.tb00605.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

In recent years, new formulations of the original amphotericin B preparation (Fungizone) have been devised in order to overcome toxicity problems that frequently occur. These preparations represent an improved method of drug delivery, with an increased therapeutic index and a decrease in toxicity to mammalian cell membranes. The new formulations have different physico-chemical characteristics and differ in pharmacokinetic parameters. Their effects must be compared with conventional amphotericin B to ascertain potential roles in future antifungal therapy.

引用

页码：147 / 153

页数：7

共 59 条

[31] TREATMENT AND PROPHYLAXIS OF DISSEMINATED INFECTION DUE TO CANDIDA-ALBICANS IN MICE WITH LIPOSOME-ENCAPSULATED AMPHOTERICIN-B
LOPEZBERESTEIN, G
MEHTA, R
HOPFER, RL
MILLS, K
KASI, L
MEHTA, K
FAINSTEIN, V
LUNA, M
HERSH, EM
JULIANO, R
[J]. JOURNAL OF INFECTIOUS DISEASES, 1983, 147 (05) : 939 - 945
[32] LIPOSOMES AS CARRIERS OF ANTIMICROBIAL AGENTS
LOPEZBERESTEIN, G
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (05) : 675 - 678
[33] LIPOSOMAL AMPHOTERICIN-B IN THE TREATMENT OF FUNGAL-INFECTIONS
LOPEZBERESTEIN, G
[J]. ANNALS OF INTERNAL MEDICINE, 1986, 105 (01) : 130 - 131
[34] MACKANESS GB, 1990, J LIPOSOMAL RES, V1, P503
[35] A REVIEW OF COMPLICATIONS OF AMPHOTERICIN-B THERAPY - RECOMMENDATIONS FOR PREVENTION AND MANAGEMENT
MADDUX, MS
BARRIERE, SL
[J]. DRUG INTELLIGENCE & CLINICAL PHARMACY, 1980, 14 (03): : 177 - 181
[36] ANTI-FUNGAL AGENTS USEFUL IN THERAPY OF SYSTEMIC FUNGAL-INFECTIONS
MEDOFF, G
BRAJTBURG, J
KOBAYASHI, GS
BOLARD, J
[J]. ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1983, 23 : 303 - 330
[37] LIPOSOMAL AMPHOTERICIN-B (AMBISOME) - SAFETY DATA FROM A PHASE-II/III CLINICAL-TRIAL
MEUNIER, F
PRENTICE, HG
RINGDEN, O
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1991, 28 : 83 - 91
[38] CURRENT ROLE OF THERAPY WITH AMPHOTERICIN-B
MEYER, RD
[J]. CLINICAL INFECTIOUS DISEASES, 1992, 14 : S154 - S160
[39] ELIMINATION OF AMPHOTERICIN-B IN IMPAIRED RENAL-FUNCTION
MORGAN, DJ
CHING, MS
RAYMOND, K
BURY, RW
MASHFORD, ML
KONG, B
SABTO, J
GURR, FW
SOMOGYI, AA
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1983, 34 (02) : 248 - 253
[40] RANDOMIZED, DOUBLE-BLIND TRIAL OF 1-HOUR VERSUS 4-HOUR AMPHOTERICIN-B INFUSION DURATIONS
OLDFIELD, EC
GARST, PD
HOSTETTLER, C
WHITE, M
SAMUELSON, D
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (07) : 1402 - 1406

← 1 2 3 4 5 6 →